Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Datopotamab Deruxtecan |
ADC | Solid Tumour | ||
|
Molecule
Datopotamab Deruxtecan
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Patritumab Deruxtecan |
ADC | Solid Tumour | ||
|
Molecule
Patritumab Deruxtecan
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Rovalpituzumab Tesirine |
ADC | Solid Tumour | ||
|
Molecule
Rovalpituzumab Tesirine
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Depatuxizumab Mafodotin |
ADC | Solid Tumour | ||
|
Molecule
Depatuxizumab Mafodotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Telisotuzumab Vedotin |
ADC | Solid Tumour | ||
|
Molecule
Telisotuzumab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Zilovertamab Vedotin |
ADC | Solid Tumour | ||
|
Molecule
Zilovertamab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Ladiratuzumab Vedotin |
ADC | Solid Tumour | ||
|
Molecule
Ladiratuzumab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Cofetuzumab Pelidotin |
ADC | Solid Tumour | ||
|
Molecule
Cofetuzumab Pelidotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Farletuzumab Ecteribulin |
ADC | Solid Tumour | ||
|
Molecule
Farletuzumab Ecteribulin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Olaratumab |
PDGFR / GD2 Targeting Agent | Solid Tumour (Sarcoma/Neuroblastoma) | ||
|
Molecule
Olaratumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
||||
Dinutuximab |
PDGFR / GD2 Targeting Agent | Solid Tumour (Sarcoma/Neuroblastoma) | ||
|
Molecule
Dinutuximab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
||||
Naxitamab |
PDGFR / GD2 Targeting Agent | Solid Tumour (Sarcoma/Neuroblastoma) | ||
|
Molecule
Naxitamab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
||||
Datopotamab DeruxtecanTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Patritumab DeruxtecanTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Rovalpituzumab TesirineTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Depatuxizumab MafodotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Telisotuzumab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Zilovertamab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Ladiratuzumab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Cofetuzumab PelidotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Farletuzumab EcteribulinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
OlaratumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
|
DinutuximabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
|
NaxitamabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
|